Publicaciones en colaboración con investigadores/as de University of Melbourne (36)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

2023

  1. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

  2. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

  2. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

2021

  1. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, Vol. 208

  2. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2020

  1. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

    Multiple Sclerosis and Related Disorders, Vol. 38

  2. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

2019

  1. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243

2018

  1. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

    Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652

2017

  1. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

    Neurology, Vol. 89, Núm. 10, pp. 1050-1059

  2. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  3. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203

  4. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357

  5. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349

  3. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

    Multiple Sclerosis, Vol. 22, Núm. 4, pp. 520-532

2015

  1. BREMSO: A simple score to predict early the natural course of multiple sclerosis

    European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989